Reining In “March In”: NIH Rejects Xtandi Petition
This article was originally published in RPM Report
Executive Summary
The National Institutes of Health is rejecting calls to exercise “march in” rights on patents for a cancer drug, declaring its view that the authority is narrowly focused on shortages – not pricing.
You may also be interested in...
End Of The 'March-In' Pricing Petitions?
KEI vows to continue battle over Bayh-Doyle restrictions after US Commerce Department suggests it may issue regulations to exclude pricing as a basis for requiring companies to license their patents.
Building A Wall? The Plan To End “March In” Threat To US Drug Patents
Calls to exercise “march in” rights on federal patents licensed to pharmaceutical companies are a recurring theme in the US drug pricing debate. Now the Department of Commerce is proposing to make those threats even emptier than they already are.
NIH Director Collins Stays On: Continuity For ‘Moonshot’ – And Barrier To ‘March In’
For industry, the sole health agency head held over from the Obama Administration means the ‘Moonshot’ priorities will move forward – and one possible threat to pricing is cut off.